focus -WSS

focus

author：hotspot 2025-09-06 02:14:04 - browse：4831

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The EU Joint Clinical Assessment needs to live up to its promise

hotspot

WSS

NIH confirmation hearing shows politicization of research

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Studies point to risks of excluding people with obesity from drug trials

The biotech scorecard for Q3: 15 stock

Hospital price transparency does save money, advocate argues

Skip the lead apron during X

hotspot

focus

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Drug cartel violence flares in western Mexico after vigilante leader's killing

Medical leaders decry Supreme Court decision on affirmative action

The wait for US passports is creating travel purgatory and snarling summer plans

Anesthesiologist group: stop taking Ozempic before surgery

The biotech scorecard for Q3: 15 stock

Heart attack and stroke risk calculators need revising

Drug cartel violence flares in western Mexico after vigilante leader's killing

Heart attack and stroke risk calculators need revising

Pharmacists can make shortage drugs, but at what cost?

knowledge

STAT Summit: Michael J. Fox on progress in Parkinson's research

Pharmacists can make shortage drugs, but at what cost?

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Fatty liver disease was alleviated by Lilly’s ‘triple

Studies point to risks of excluding people with obesity from drug trials

focus

hotspot

focus

hotspot